KR20250065937A - Mtorc1 조절제 및 이의 용도 - Google Patents
Mtorc1 조절제 및 이의 용도 Download PDFInfo
- Publication number
- KR20250065937A KR20250065937A KR1020257014654A KR20257014654A KR20250065937A KR 20250065937 A KR20250065937 A KR 20250065937A KR 1020257014654 A KR1020257014654 A KR 1020257014654A KR 20257014654 A KR20257014654 A KR 20257014654A KR 20250065937 A KR20250065937 A KR 20250065937A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- salt
- alkyl
- optionally substituted
- membered heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Burglar Alarm Systems (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (16)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001144P | 2020-03-27 | 2020-03-27 | |
| US202063001177P | 2020-03-27 | 2020-03-27 | |
| US202063001187P | 2020-03-27 | 2020-03-27 | |
| US63/001,177 | 2020-03-27 | ||
| US63/001,144 | 2020-03-27 | ||
| US63/001,187 | 2020-03-27 | ||
| US202063019176P | 2020-05-01 | 2020-05-01 | |
| US63/019,176 | 2020-05-01 | ||
| US202063054768P | 2020-07-21 | 2020-07-21 | |
| US202063054763P | 2020-07-21 | 2020-07-21 | |
| US202063054762P | 2020-07-21 | 2020-07-21 | |
| US63/054,762 | 2020-07-21 | ||
| US63/054,763 | 2020-07-21 | ||
| US63/054,768 | 2020-07-21 | ||
| PCT/US2021/024536 WO2021195599A1 (en) | 2020-03-27 | 2021-03-26 | Mtorc1 modulators and uses thereof |
| KR1020227036354A KR102805250B1 (ko) | 2020-03-27 | 2021-03-26 | Mtorc1 조절제 및 이의 용도 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227036354A Division KR102805250B1 (ko) | 2020-03-27 | 2021-03-26 | Mtorc1 조절제 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250065937A true KR20250065937A (ko) | 2025-05-13 |
Family
ID=77892684
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257014654A Pending KR20250065937A (ko) | 2020-03-27 | 2021-03-26 | Mtorc1 조절제 및 이의 용도 |
| KR1020227036354A Active KR102805250B1 (ko) | 2020-03-27 | 2021-03-26 | Mtorc1 조절제 및 이의 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227036354A Active KR102805250B1 (ko) | 2020-03-27 | 2021-03-26 | Mtorc1 조절제 및 이의 용도 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11634432B2 (https=) |
| EP (1) | EP4126229A4 (https=) |
| JP (2) | JP7606591B2 (https=) |
| KR (2) | KR20250065937A (https=) |
| CN (2) | CN115776907B (https=) |
| AU (2) | AU2021241718B2 (https=) |
| CA (1) | CA3173722A1 (https=) |
| IL (1) | IL296828A (https=) |
| MX (1) | MX2022011964A (https=) |
| WO (1) | WO2021195599A1 (https=) |
| ZA (1) | ZA202210888B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| IL285067B2 (en) | 2019-01-22 | 2025-02-01 | Aeovian Pharmaceuticals Inc | MTORC Modulators and Their Uses |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| CN121426814A (zh) * | 2020-07-21 | 2026-01-30 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| EP4688148A1 (en) * | 2023-04-07 | 2026-02-11 | Regeneron Pharmaceuticals, Inc. | Selective rapamycin analogs and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
| SK78196A3 (en) | 1993-12-17 | 1997-02-05 | Sandoz Ag | Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them |
| US6187757B1 (en) * | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| JP2002508971A (ja) * | 1998-01-15 | 2002-03-26 | アリアド・ジーン・セラピューティクス・インコーポレーテッド | 多量体キメラ蛋白質を使用する生物学的イベントの調節 |
| ATE264863T1 (de) * | 1999-08-24 | 2004-05-15 | Ariad Gene Therapeutics Inc | 28-epirapaloge |
| WO2006136175A2 (en) | 2005-06-22 | 2006-12-28 | Lifecycle Pharma A/S | Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor |
| GB0601406D0 (en) | 2006-01-24 | 2006-03-08 | Novartis Ag | Organic Compounds |
| US20110098241A1 (en) | 2008-04-14 | 2011-04-28 | Poniard Pharmaceuticals, Inc. | Rapamycin analogs as anti-cancer agents |
| CN103391780B (zh) * | 2011-02-16 | 2015-08-19 | 诺瓦提斯公司 | 用于治疗神经变性疾病的治疗剂的组合物 |
| US20160138027A1 (en) * | 2013-03-14 | 2016-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| ES2857226T3 (es) * | 2014-03-15 | 2021-09-28 | Novartis Ag | Receptor de antígeno quimérico regulable |
| CN113620978A (zh) | 2014-09-11 | 2021-11-09 | 加利福尼亚大学董事会 | mTORC1抑制剂 |
| JP6793652B2 (ja) | 2015-09-03 | 2020-12-02 | 日本化薬株式会社 | ラパマイシン又はその誘導体を含有する医薬組成物 |
| US10683308B2 (en) * | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| CN108926533B (zh) | 2017-05-24 | 2022-03-25 | 江苏天士力帝益药业有限公司 | 一种替西罗莫司脂质体及其制备方法 |
| US10478561B2 (en) | 2017-08-03 | 2019-11-19 | Minhong Yu | Wireless transmission system with integrated sensing capability |
| AR112834A1 (es) | 2017-09-26 | 2019-12-18 | Novartis Ag | Derivados de rapamicina |
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| WO2020076738A2 (en) | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| HRP20250197T1 (hr) | 2018-12-18 | 2025-04-11 | Novartis Ag | Derivati rapamicina |
| IL285067B2 (en) | 2019-01-22 | 2025-02-01 | Aeovian Pharmaceuticals Inc | MTORC Modulators and Their Uses |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| CN115776907B (zh) | 2020-03-27 | 2025-02-25 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| CN121426814A (zh) | 2020-07-21 | 2026-01-30 | 艾奥维安制药公司 | Mtorc1调节剂及其用途 |
| US20220267352A1 (en) | 2021-01-22 | 2022-08-25 | Anakuria Therapeutics, Inc. | Rapamycin analogs and uses thereof |
-
2021
- 2021-03-26 CN CN202180038254.0A patent/CN115776907B/zh active Active
- 2021-03-26 EP EP21775952.1A patent/EP4126229A4/en active Pending
- 2021-03-26 IL IL296828A patent/IL296828A/en unknown
- 2021-03-26 CA CA3173722A patent/CA3173722A1/en active Pending
- 2021-03-26 AU AU2021241718A patent/AU2021241718B2/en active Active
- 2021-03-26 CN CN202510123209.5A patent/CN119954829A/zh active Pending
- 2021-03-26 MX MX2022011964A patent/MX2022011964A/es unknown
- 2021-03-26 KR KR1020257014654A patent/KR20250065937A/ko active Pending
- 2021-03-26 WO PCT/US2021/024536 patent/WO2021195599A1/en not_active Ceased
- 2021-03-26 KR KR1020227036354A patent/KR102805250B1/ko active Active
- 2021-03-26 JP JP2023502874A patent/JP7606591B2/ja active Active
-
2022
- 2022-03-01 US US17/683,549 patent/US11634432B2/en active Active
- 2022-06-03 US US17/832,240 patent/US11603377B2/en active Active
- 2022-10-03 ZA ZA2022/10888A patent/ZA202210888B/en unknown
-
2023
- 2023-03-08 US US18/180,517 patent/US20240002399A1/en active Pending
-
2024
- 2024-12-13 JP JP2024218609A patent/JP7645431B2/ja active Active
-
2025
- 2025-06-25 AU AU2025204768A patent/AU2025204768C1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11603377B2 (en) | 2023-03-14 |
| CN115776907A (zh) | 2023-03-10 |
| US20220235069A1 (en) | 2022-07-28 |
| AU2025204768A1 (en) | 2025-07-17 |
| US20240002399A1 (en) | 2024-01-04 |
| JP7606591B2 (ja) | 2024-12-25 |
| CA3173722A1 (en) | 2021-09-30 |
| JP7645431B2 (ja) | 2025-03-13 |
| WO2021195599A1 (en) | 2021-09-30 |
| EP4126229A1 (en) | 2023-02-08 |
| KR20230084095A (ko) | 2023-06-12 |
| AU2025204768B2 (en) | 2025-08-07 |
| CN119954829A (zh) | 2025-05-09 |
| AU2025204768C1 (en) | 2026-02-05 |
| IL296828A (en) | 2022-11-01 |
| US11634432B2 (en) | 2023-04-25 |
| AU2021241718A1 (en) | 2022-10-20 |
| AU2021241718B2 (en) | 2025-03-27 |
| CN115776907B (zh) | 2025-02-25 |
| BR112022019508A2 (pt) | 2022-11-16 |
| MX2022011964A (es) | 2022-12-02 |
| JP2025028197A (ja) | 2025-02-28 |
| EP4126229A4 (en) | 2024-04-17 |
| US20220332727A1 (en) | 2022-10-20 |
| KR102805250B1 (ko) | 2025-05-08 |
| ZA202210888B (en) | 2024-02-28 |
| JP2023530778A (ja) | 2023-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102805250B1 (ko) | Mtorc1 조절제 및 이의 용도 | |
| CN104725359B (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| TWI723511B (zh) | 一種高活性sting蛋白激動劑化合物 | |
| AU2016322848B2 (en) | 1-phenylpyrrolidin-2-one derivatives as perk inhibitors | |
| CA3120514A1 (en) | Cyclic ureas | |
| CN116322677B (zh) | Mtorc1调节剂及其用途 | |
| JP2022553273A (ja) | 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤 | |
| JP7585205B2 (ja) | 二環式ピロロトリアゾールケトン化合物及びその使用方法 | |
| TW202321244A (zh) | 一種Ｗｎｔ通路抑制劑化合物 | |
| TW202304906A (zh) | 高活性hpk1激酶抑制劑 | |
| BR112022019508B1 (pt) | MODULADORES DE mTORC1 E SEUS USOS | |
| BR122024006050B1 (pt) | MODULADORES DE mTORC1 E SEUS USOS | |
| BR122024006050A2 (pt) | Moduladores de mtorc1 e seus usos | |
| HK40096020A (zh) | Mtorc1调节剂及其用途 | |
| HK40096020B (zh) | Mtorc1调节剂及其用途 | |
| CN106065018A (zh) | 取代的吲哚化合物及其使用方法和用途 | |
| WO2025185736A1 (zh) | 一种多元螺环化合物的晶型、其制备方法和医药用途 | |
| WO2025185734A1 (zh) | 一种多元螺环化合物的盐及其晶型、其制备方法和医药用途 | |
| KR20160098498A (ko) | 피라졸 유도체 및 dlk의 억제제로서 이의 용도 | |
| HK1209114B (en) | 3-substituted pyrazoles and use as dlk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| PA0302 | Request for accelerated examination |
St.27 status event code: A-1-2-D10-D16-exm-PA0302 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |